Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
NCT ID: NCT02147873
Last Updated: 2016-10-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
118 participants
INTERVENTIONAL
2014-06-30
2016-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)
NCT04266301
Azacitidine Plus Phenylbutyrate in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT00004871
Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
NCT00666497
A Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic Syndromes
NCT02508870
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
NCT01522976
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The primary purpose of this study is :
-To compare the relative effect of azacitidine plus birinapant versus azacitidine plus placebo on response rate in patients with higher-risk MDS, secondary MDS or CMMoL.
The secondary purpose of this study is to compare effect of azacitidine plus birinapant relative to azacitidine with placebo on:
* Hematologic improvement
* Relapse free survival
* Time to respond
* Change in transfusion requirements
* Duration of response
* Overall survival
* Adverse events
The exploratory objective of this study is to assess exploratory translational biomarkers for antitumor effects.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
azacitidine with birinapant
Azacitidine 75 mg/m2 IV on days 1-5, 8 \& 9 OR days 1-7 and birinapant 13 mg/m2 IV twice a week (days 1 \& 4) for 3 out of 4 weeks
birinapant
Azacitidine
Azacitidine and placebo
Azacitidine 75mg/m2 IV days 1-5, 8 \& 9 OR days 1-7 and placebo IV twice a week (days 1 \& 4) for 3 out of 4 weeks
Azacitidine
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
birinapant
Azacitidine
Placebo
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* International prognostic score-revised (IPSS-R) of \>3.5 (Intermediate, High or Very High)
* Previously untreated with hypomethylating agents for MDS/CMMoL
* Performance status of 0, 1 or 2 by the ECOG scale
* Adequate renal and liver function
* Female subjects of childbearing potential must have a negative serum pregnancy test at screening within 96 hours prior to the first study dose.
* Female subjects of childbearing potential and male subjects with partners of childbearing potential should ensure use of a highly effective method of birth control as defined by the investigator, for example, those which result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly during the study and for a period of 3 months following the last dose of any drug administered during the study.
Exclusion Criteria
* Acute myeloid leukemia (AML), except those patients with RAEB-t who are not candidates for intensive AML therapy.
* Participated in any interventional study within 4 weeks of randomization or 5 half lives (whichever is longer).
* Received any hematopoietic growth factors within 14 days prior to screening.
* Prior malignancy or secondary malignancy within the prior 2 years (except in situ cervical cancer, squamous cell carcinoma or basal cell carcinoma of the skin).
* known diagnosis of human immunodeficiency virus or chronic active Hep B or C.
* Uncontrolled hypertension
* Impaired cardiac function, uncontrolled cardiac arrhythmias despite medications, or clinically significant cardiac disease
* Lack of recovery of prior adverse events to Grade ≤1 severity (National Cancer Institute Common Terminology Criteria for Adverse Events version 4) (except alopecia) due to therapy administered prior to the initiation of study drug dosing.
* Nursing or pregnant.
* Known allergy or hypersensitivity to any of the formulation components
* Any concurrent disease and/or medical condition that, in the opinion of the Investigator, would prevent the subject's participation.
* History of cranial nerve palsy.
* Being treated with anti-TNF therapies or has been treated with an anti-TNF therapy within 5 half-lives of randomization.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
TetraLogic Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Palo Verde Hematology Oncology
Glendale, Arizona, United States
Arizona Center for Cancer Care
Glendale, Arizona, United States
Mayo Clinic
Scottsdale, Arizona, United States
Arizona Oncology Associates
Tucson, Arizona, United States
Ronald Reagan UCLA Medical Center
Los Angeles, California, United States
North County Oncology
Oceanside, California, United States
Desert Hematology Oncology Medical Group
Rancho Mirage, California, United States
Stanford Hospital and Clinics
Stanford, California, United States
Wellness Oncology & Hematology
West Hills, California, United States
Colorado Blood Cancer Institute
Denver, Colorado, United States
Cancer Specialists of North Florida
Jacksonville, Florida, United States
Mayo Clinic Jacksonville
Jacksonville, Florida, United States
Hematology Oncology Associates of the Treasure Coast
Port Saint Lucie, Florida, United States
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida, United States
Bond Clinic PA
Winter Haven, Florida, United States
Loyola University Medical Center
Maywood, Illinois, United States
Simmons Cancer Institute at Southern Illinois University
Springfield, Illinois, United States
University of Iowa Hospitals and Clinics
Iowa City, Iowa, United States
University of Louisville Hospital/James Graham Brown Cancer Center
Louisville, Kentucky, United States
Tulane Medical Center
New Orleans, Louisiana, United States
University of Maryland, Greenebaum Cancer Center
Baltimore, Maryland, United States
University of Massachusetts Worcester
Worcester, Massachusetts, United States
St. Joseph Mercy Hospital
Ann Arbor, Michigan, United States
New Jersey Hematology Oncology Associates
Brick, New Jersey, United States
Hackensack University Medical Center
Hackensack, New Jersey, United States
University of New Mexico Cancer Center
Albuquerque, New Mexico, United States
North Shore Hematology Oncology Associates
East Setauket, New York, United States
Monter Cancer Center
Lake Success, New York, United States
Columbia University Medical Center
New York, New York, United States
Weill Cornell Medical College - New York-Presbyterian Hospital
New York, New York, United States
Montefiore Medical Center
The Bronx, New York, United States
Duke University Medical Center
Durham, North Carolina, United States
Gabrail Cancer Center Research
Canton, Ohio, United States
Oncology Hematology Care, Inc.
Cincinnati, Ohio, United States
Oregon Health and Sciences University
Portland, Oregon, United States
Penn State Milton S. Hershey Medical Center
Hershey, Pennsylvania, United States
Medical University of South Carolina, Hollings Cancer Center
Charleston, South Carolina, United States
Carolina Blood and Cancer Care Associates, P.A.
Rock Hill, South Carolina, United States
Tennessee Oncology
Chattanooga, Tennessee, United States
Tennessee Oncology
Nashville, Tennessee, United States
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Tyler Hematology Oncology PA
Tyler, Texas, United States
Utah Cancer Specialists
Salt Lake City, Utah, United States
University of Utah, Huntsman Cancer Hospital
Salt Lake City, Utah, United States
Virginia Commonwealth University Massey Cancer Center
Richmond, Virginia, United States
Seattle Cancer Care Alliance
Seattle, Washington, United States
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia
Westmead Hospital
Westmead, New South Wales, Australia
Metro South Health, Princess Alexandra Hospital
Woolloongabba, Queensland, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
Royal Hobart Hospital
Hobart, Tasmania, Australia
Austin Health
Heidelberg, Victoria, Australia
Cabrini Hospital
Malvern, Victoria, Australia
The Alfred
Melbourne, Victoria, Australia
Border Medical Oncology
Wodonga, Victoria, Australia
Perth Blood Institute
Nedlands, Western Australia, Australia
Klinikum der Ludwig-Maximilians-Universitat Munchen
Munich, Bavaria, Germany
Klinikum Rechts der Isar, Technischen Universitat Munchen
München, Bavaria, Germany
University Hospital of Cologne
Cologne, North Rhine-Westphalia, Germany
Marien Hospital Dusseldorf
Düsseldorf, North Rhine-Westphalia, Germany
University Hospital Halle
Halle, Saxony-Anhalt, Germany
Universitatsklinikum Essen
Essen, , Germany
Medizinische Hochschule Hannover
Hanover, , Germany
Medizinische Universitatsklinik Heidelberg
Heidelberg, , Germany
Universitatsklinikum Wurzburg
Würzburg, , Germany
Hospital Germans Trias I Pujol
Badalona, Badalona, Spain
Hospital University Reina Sofia
Córdoba, Cordoba, Spain
Hospital Universitario Severo Ochoa
Leganés, Madrid, Spain
Hospital Universitario Gregorio Maranon
Madrid, Madrid, Spain
MD Anderson Cancer Center
Madrid, Madrid, Spain
Hospital Clinico Universitario Virgen de la Arrixaca
El Palmar, Murcia, Spain
Clinica Universidad de Navarra
Pamplona, Navarre, Spain
Hospital Universitario de Canarias
San Cristóbal de La Laguna, S/C Tenerife, Spain
Hospital Universitario de Salamanca
Salamanca, Salamanca, Spain
Complejo Hospitalario Virgen de la Salud
Toledo, Toledo, Spain
Hospital Clinico Universitario de Valencia
Valencia, Valencia, Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2014-001719-37
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
TL32711-RAN-0094-PTL
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.